CVX vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Chevron Corporation and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
Chevron Corporation · Energy
$193.33
-18.2% upside to fair value
Grade D
VS
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
QuantHub Verdict
JNJ has more upside to fair value
(+10.8%).
JNJ trades at a lower forward P/E
(26.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CVX |
JNJ |
| Current Price |
$193.33 |
$230.69 |
| Fair Value Estimate |
$158.09 |
$255.61 |
| Upside to Fair Value |
-18.2%
|
+10.8%
|
| Market Cap |
$385.8B |
$555.9B |
| Forward P/E |
31.3x
|
26.8x
|
| EV / EBITDA |
10.3x
|
18.5x
|
| Price / Sales |
2.1x
|
5.8x
|
| Price / FCF |
23.8x
|
28.2x
|
| Revenue Growth YoY |
-5.3%
|
+9.9%
|
| Gross Margin |
30.4%
|
69.1%
|
| Operating Margin |
9.0%
|
26.9%
|
| Return on Equity |
7.3%
|
26.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.19%
|
3.54%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Chevron Corporation operates as a leading integrated oil and gas company with significant upstream and downstream operations. The company benefits from experienced leadership under CEO Mike Wirth, who has over 44 years with Chevron, and maintains a strong market position as the second largest Big Oil major by market cap and net profits. However, Chevron currently trades at a very expensive valuat…
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Accumulation Zones
| Metric |
CVX |
JNJ |
| Zone Low |
$118.57 |
$191.71 |
| Zone High |
$134.38 |
$217.27 |
| In Buy Zone? |
No
|
No
|